Actively Recruiting
Exploring the Novel Value of PSMA PET in Sj f6gren's Syndrome: Integrated Analysis With Established FAPI PET Imaging
Led by Peking Union Medical College Hospital · Updated on 2026-01-07
60
Participants Needed
1
Research Sites
17 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Primary Sj f6gren's syndrome (pSS) is a chronic autoimmune disease that affects the salivary glands, leading to inflammation, damage, and loss of gland function. Researchers are evaluating a new imaging approach using two types of PET scans, PSMA PET and FAPI PET, to better understand and measure both gland function and inflammation simultaneously. This method could improve disease staging and guide treatment decisions by capturing the complex biological changes in pSS. Participants diagnosed with pSS will undergo both PSMA PET and FAPI PET imaging to assess salivary gland function and inflammation. Another group of patients with prostate cancer will have PSMA PET scans only, serving as a reference for normal salivary gland function. The study aims to develop a combined PSMA/FAPI Index that integrates both imaging signals to characterize disease activity and progression. During the study, participants will receive PET scans that measure salivary gland function and inflammatory activity. Researchers will compare these imaging results with clinical indicators to understand their relationship. They will measure differences in tracer uptake between groups and explore how PSMA and FAPI signals relate spatially and quantitatively. The study will provide important data for noninvasive disease monitoring and may help predict responses to therapy. Participation involves scheduled imaging visits and clinical assessments over the study period.
CONDITIONS
Brief Title
Exploring the Novel Value of PSMA PET in Sjögren's Syndrome: Integrated Analysis With Established FAPI PET Imaging
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-80 years
- Meeting the 2016 ACR-EULAR Classification Criteria for primary Sj�f6gren's syndrome at enrollment or diagnosis of a solid tumor scheduled for FAPI PET imaging
You will not qualify if you...
- Presence of tumors or other connective tissue diseases (for the Sj�f6gren's syndrome group)
- Current use of hormones or biological agents (for both groups)
- Pregnancy or lactation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single visit
Participants undergo PET imaging scans to assess salivary gland function and inflammation. Those with primary Sjögren's syndrome receive both PSMA and FAPI PET scans, while prostate cancer patients receive PSMA PET imaging only as a comparator.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, China
Actively Recruiting
Research Team
Z
Zhaohui Zhu, MD
J
Jiarou Wang, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here